StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.1
Power Rank trend -> Rising
03/27/2025 16:24:00 EST
TG Therapeutics Inc (TGTX)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, TGTX has been trading in a range between $42.99 and $28.53 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
TGTX is trading below resistance at $42.99, about 7% to the upside. There is support at $32.26 -20% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
TG Therapeutics Inc $TGTX entered a Green zone 18 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $40.875, a potential upside of 0.21% from the recent price of 40.79. The stock is trading 6.2% (potential upside) below its 52 week high of $43.32 and 215.47 % (potential downside) above its 52 week low of $12.93 - based on the recent price.
Company Summary
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
News
| These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles Insurance stock Root soared to a new high on Friday. The IBD 50 holding has an ideal Composite and Relative Strength Rating. Source: Investors Business Daily Fri, 21 Mar 2025 15:22:45 -0400 Sentiment: Positive |
| Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher Trading is subdued with TG Therapeutics, Inc. TGTX on Friday. But the shares remain in an uptrend and there is a good chance the trend will continue. Source: Benzinga Fri, 21 Mar 2025 11:50:25 -0400 Sentiment: Positive |
| Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. Source: Zacks Investment Research Mon, 17 Mar 2025 06:35:25 -0400 Sentiment: Positive |
| Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer and autoimmune disorders. TG Therapeutics' BRIUMVI achieved significant sales growth in 2024, supporting positive cash flow and funding for future developments, including azer-cel for autoimmune disorders. DTIL is rated a speculative "Buy" due to its undervaluation, promising pipeline, and strategic partnerships, while TGTX is rated "Hold" due to its full valuation. Source: Seeking Alpha Sat, 15 Mar 2025 08:42:25 -0400 Sentiment: Positive |
| TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient convenience and treatment efficacy. Source: Seeking Alpha Fri, 14 Mar 2025 14:04:04 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 43.32 52 Week Low: 12.93 Beta: 2.301 50 Day MA: 34.1476 200 Day MA: 27.0762 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.973 Qtr Revenue Growth YOY: 1.46 Forward PE: 28.9017 Trailing PE: 268